Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
Pharma IQ's 2nd Annual Innovation in Phase I Clinical DevelopmentNicola Abbott
Register and pay before 22nd July 2011 to save up to €350 for the 2nd annual Phase 1 Clinical Development conference in Verona, Italy from September 12-14, 2011. The conference will provide exclusive access to Aptuit's world-class research facilities and allow attendees to engage with leading regulators, learn from industry experts, and develop strategies to prevent late stage clinical failure and make informed early phase decisions. Unique events include an exclusive behind-the-scenes tour of Aptuit's facilities and interactive breakout sessions to exchange ideas with peers.
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
2nd Annual Bioequivalence and Bioavailability Studies 2011 - AgendaPharma IQ
2nd Annual Bioequivalence and Bioavailability Studies - Full Agenda
LEARN MORE
http://www.bioequivalenceevent.com/redForms.aspx?id=532198&pdf_form=1?&shownewswindow=1&utm_source=PharmaIQ&utm_medium=SMO&mac=PMIQ_Slideshare&utm_campaign=Slideshare&utm_term=pdf
This document discusses clinical proof-of-concept (POC) trials in drug development. It defines POC as establishing whether a drug is reasonably likely to succeed based on early evidence of safety and efficacy. The document outlines goals of POC trials, decision criteria used, and strategies to improve probability of success such as better patient selection using biomarkers. It provides examples of oncology POC trials and discusses practical considerations for using patient selection approaches.
Speaker: Wendy Hill, Gap Strategies. Part of the MaRS Best Practices Series.This session, led by seasoned industry experts, will explore how to effectively set up your pre-clinical POC studies, address pre-clinical safety requirements and issues, and give you an overview of the manufacturing standards required for Phase I studies
More information: http://www.marsdd.com/Events/Event-Calendar/Best-Practices-Series/ind-05132008.html
The document discusses the high failure rate and costs of drug development, and the need for new solutions to address safety and efficacy challenges. It introduces biomarkers as a key solution, noting they can help improve discovery, clinical development, and portfolio management by identifying drugs more likely to succeed in early trials. Biomarker services aim to determine proof-of-concept earlier at lower cost by providing predictive indicators of drug function, response, efficacy, and safety through tissue analysis and protein detection.
Exploratory Clinical Trials conference, being held Tuesday 1 and Wednesday 2 December 2009 in Brussels, Belgium, will bring experts from the pharmaceutical and biotech industry together to discuss these issues and the latest developments within the field of exploratory clinical trials. Through a series of presentation, case studies and interactive discussions, participants will gain practical insight into key issues such as gaining regulatory approval, implementing and running exploratory studies successfully and efficiently, the role of biomarkers, utilising effective modelling and simulations tools as well as the mitigation of safety risks.
This document provides information about an upcoming conference on peptides to be held June 30 - July 2, 2014 in London. It will focus on peptide formulation, delivery, characterization, and development of new peptide drugs. The conference will feature keynote speakers from pharmaceutical companies discussing topics such as oral delivery of peptides and peptide drug manufacturing. An interactive workshop on extending peptide half-life will also be held. The event is aimed at strengthening knowledge of peptide therapeutic development and assessment.
Pharma IQ's 2nd Annual Innovation in Phase I Clinical DevelopmentNicola Abbott
Register and pay before 22nd July 2011 to save up to €350 for the 2nd annual Phase 1 Clinical Development conference in Verona, Italy from September 12-14, 2011. The conference will provide exclusive access to Aptuit's world-class research facilities and allow attendees to engage with leading regulators, learn from industry experts, and develop strategies to prevent late stage clinical failure and make informed early phase decisions. Unique events include an exclusive behind-the-scenes tour of Aptuit's facilities and interactive breakout sessions to exchange ideas with peers.
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
2nd Annual Bioequivalence and Bioavailability Studies 2011 - AgendaPharma IQ
2nd Annual Bioequivalence and Bioavailability Studies - Full Agenda
LEARN MORE
http://www.bioequivalenceevent.com/redForms.aspx?id=532198&pdf_form=1?&shownewswindow=1&utm_source=PharmaIQ&utm_medium=SMO&mac=PMIQ_Slideshare&utm_campaign=Slideshare&utm_term=pdf
This document discusses clinical proof-of-concept (POC) trials in drug development. It defines POC as establishing whether a drug is reasonably likely to succeed based on early evidence of safety and efficacy. The document outlines goals of POC trials, decision criteria used, and strategies to improve probability of success such as better patient selection using biomarkers. It provides examples of oncology POC trials and discusses practical considerations for using patient selection approaches.
Speaker: Wendy Hill, Gap Strategies. Part of the MaRS Best Practices Series.This session, led by seasoned industry experts, will explore how to effectively set up your pre-clinical POC studies, address pre-clinical safety requirements and issues, and give you an overview of the manufacturing standards required for Phase I studies
More information: http://www.marsdd.com/Events/Event-Calendar/Best-Practices-Series/ind-05132008.html
The document discusses the high failure rate and costs of drug development, and the need for new solutions to address safety and efficacy challenges. It introduces biomarkers as a key solution, noting they can help improve discovery, clinical development, and portfolio management by identifying drugs more likely to succeed in early trials. Biomarker services aim to determine proof-of-concept earlier at lower cost by providing predictive indicators of drug function, response, efficacy, and safety through tissue analysis and protein detection.
Exploratory Clinical Trials conference, being held Tuesday 1 and Wednesday 2 December 2009 in Brussels, Belgium, will bring experts from the pharmaceutical and biotech industry together to discuss these issues and the latest developments within the field of exploratory clinical trials. Through a series of presentation, case studies and interactive discussions, participants will gain practical insight into key issues such as gaining regulatory approval, implementing and running exploratory studies successfully and efficiently, the role of biomarkers, utilising effective modelling and simulations tools as well as the mitigation of safety risks.
This document provides information about an upcoming conference on peptides to be held June 30 - July 2, 2014 in London. It will focus on peptide formulation, delivery, characterization, and development of new peptide drugs. The conference will feature keynote speakers from pharmaceutical companies discussing topics such as oral delivery of peptides and peptide drug manufacturing. An interactive workshop on extending peptide half-life will also be held. The event is aimed at strengthening knowledge of peptide therapeutic development and assessment.
The medication safety project had two aims: 1) to identify areas of exposure to risk and make recommendations to enhance medication safety, and 2) to inform the development of a medication safety checklist specific to operating rooms. An interdisciplinary team conducted a review of medication use in operating rooms and related areas. They observed environments where medications were prescribed, stored, prepared, dispensed and administered. The team made recommendations in areas like improving documentation of patient medication histories, reducing abbreviations, enhancing pharmacist support, and standardizing medication storage, labeling and carts. Many of the recommendations have been implemented.
Drug discovery and evaluation safety and pharmacokinetic assaysSpringer
MRI can be used to noninvasively measure liver volume in rats over multiple time points, reducing animal usage compared to terminal procedures. A high-resolution 3D MRI scan is used to segment the liver in images, and liver volume strongly correlates with wet liver weight. Respiratory triggering during acquisition improves accuracy. MRI allows longitudinal studies where the same animals act as their own controls, increasing statistical power and reducing group sizes compared to sacrificing animals at each time point.
The document provides an overview of drug development and the biotechnology industry. It discusses the traditional and contemporary business models in the industry, which have shifted from closed innovation to more open innovation. It also outlines the services offered by one company, including clinical development support and regulatory consultancy. The document describes the company's research interests in areas like vaccines, proteins, and monoclonal antibodies. It includes organizational charts and provides details about the company's project pipeline across various phases of drug development. Finally, it discusses challenges in the industry like high costs and manufacturing techniques for cost reduction.
This document summarizes Session III of a conference on pre-clinical proof-of-concept and development. The session includes an overview, discussions on what makes a clinical candidate, IND requirements, optimization of mouse models of neurodegeneration, and the value of biomarkers in preclinical development. Specific topics covered include target selection, lead optimization, pre-clinical safety and efficacy assessments, regulatory interactions, clinical trial design, and development of appropriate clinical outcomes measures. The goal is to highlight factors to consider in selecting viable clinical candidates and preparing for first-in-human studies.
The document summarizes a session on designing drugs for central nervous system target classes. The session will include talks on:
1. Targeting protein-protein interactions, which is becoming more feasible as a drug strategy.
2. Challenges in targeting kinases for neurodegenerative diseases.
3. Considerations for druggability of G protein-coupled receptors and ion channels.
4. Unique challenges and lessons learned from developing biologics for difficult targets.
At the Exploratory Clinical Trials event on 8-9 December 2009 in Brussels, Belgium you’ll have the opportunity to question the MHRA in person on the updated ICH M3 guidelines and find out how you can maximise your chance of easily gaining approval for your trials.
SMi's 8th conference on Controlled Release builds upon the successes of the previous years in bringing together leading industry figures and tackling some of the most current and pressing issues faced by this important branch of drug development.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
Immunotherapy Europe Speakers - The Perfect Combination of Strategy and Innov...Michael Adeniya
This document lists over 40 speakers that will be presenting at an upcoming conference. The speakers represent a variety of pharmaceutical and biotech companies, academic institutions, and regulatory agencies. They will be discussing topics related to cellular therapy, immuno-oncology, combination therapies, and other areas of cancer research and treatment.
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Dancey Clinical Trials Vancouver Dancey 20110302 Final.Ppt [Compatibility Mode]Warren Hamilton
High content clinical trials involve dense sample collection and complex analyses from small patient numbers. They are important for early drug development and evaluation, addressing biological questions about target and pathway inhibition. Successful high content trials require standardized assays and infrastructure across sites, as well as collaboration between multiple institutions. Challenges include developing new science and technologies, building collaborative partnerships, and establishing operational and informatics systems for specimen and data management.
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
NCTR is a research center within the FDA that conducts toxicology research to support risk assessment and regulatory decision making. It has unique facilities including primate and BSL-3 laboratories. NCTR research focuses on emerging issues like nanotechnology, nutrition, and critical path initiatives. Bioimaging technologies like microPET and MRI are used to study effects of substances like ketamine anesthesia on brain development in primates. Studies found ketamine increased neuronal cell death markers in the frontal cortex of developing monkeys.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
The medication safety project had two aims: 1) to identify areas of exposure to risk and make recommendations to enhance medication safety, and 2) to inform the development of a medication safety checklist specific to operating rooms. An interdisciplinary team conducted a review of medication use in operating rooms and related areas. They observed environments where medications were prescribed, stored, prepared, dispensed and administered. The team made recommendations in areas like improving documentation of patient medication histories, reducing abbreviations, enhancing pharmacist support, and standardizing medication storage, labeling and carts. Many of the recommendations have been implemented.
Drug discovery and evaluation safety and pharmacokinetic assaysSpringer
MRI can be used to noninvasively measure liver volume in rats over multiple time points, reducing animal usage compared to terminal procedures. A high-resolution 3D MRI scan is used to segment the liver in images, and liver volume strongly correlates with wet liver weight. Respiratory triggering during acquisition improves accuracy. MRI allows longitudinal studies where the same animals act as their own controls, increasing statistical power and reducing group sizes compared to sacrificing animals at each time point.
The document provides an overview of drug development and the biotechnology industry. It discusses the traditional and contemporary business models in the industry, which have shifted from closed innovation to more open innovation. It also outlines the services offered by one company, including clinical development support and regulatory consultancy. The document describes the company's research interests in areas like vaccines, proteins, and monoclonal antibodies. It includes organizational charts and provides details about the company's project pipeline across various phases of drug development. Finally, it discusses challenges in the industry like high costs and manufacturing techniques for cost reduction.
This document summarizes Session III of a conference on pre-clinical proof-of-concept and development. The session includes an overview, discussions on what makes a clinical candidate, IND requirements, optimization of mouse models of neurodegeneration, and the value of biomarkers in preclinical development. Specific topics covered include target selection, lead optimization, pre-clinical safety and efficacy assessments, regulatory interactions, clinical trial design, and development of appropriate clinical outcomes measures. The goal is to highlight factors to consider in selecting viable clinical candidates and preparing for first-in-human studies.
The document summarizes a session on designing drugs for central nervous system target classes. The session will include talks on:
1. Targeting protein-protein interactions, which is becoming more feasible as a drug strategy.
2. Challenges in targeting kinases for neurodegenerative diseases.
3. Considerations for druggability of G protein-coupled receptors and ion channels.
4. Unique challenges and lessons learned from developing biologics for difficult targets.
At the Exploratory Clinical Trials event on 8-9 December 2009 in Brussels, Belgium you’ll have the opportunity to question the MHRA in person on the updated ICH M3 guidelines and find out how you can maximise your chance of easily gaining approval for your trials.
SMi's 8th conference on Controlled Release builds upon the successes of the previous years in bringing together leading industry figures and tackling some of the most current and pressing issues faced by this important branch of drug development.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Dr. Nick Thomas 17:00 - 17:30 Closing Remarks & Networking Drinks
Investigator, Molecular Discovery Research Principal Scientist
Glax
Dr. Alastair Brown Dr. Rochdi Bouhelal 15:00 - 15:30 Coffee & Networking Break
Associate Principal Scientist Senior Investigator
AstraZeneca Novartis
15:30 - 17:00 Panel Discussion & Q&A
Panelist: Dr. Magalie Rocheville Moderator: John Shah 17:00 Close
Investigator, Molecular Discovery Research Conference Producer
GlaxoSmithKline
This interactive workshop will provide a comprehensive overview of label-free cell-based
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
Immunotherapy Europe Speakers - The Perfect Combination of Strategy and Innov...Michael Adeniya
This document lists over 40 speakers that will be presenting at an upcoming conference. The speakers represent a variety of pharmaceutical and biotech companies, academic institutions, and regulatory agencies. They will be discussing topics related to cellular therapy, immuno-oncology, combination therapies, and other areas of cancer research and treatment.
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Dancey Clinical Trials Vancouver Dancey 20110302 Final.Ppt [Compatibility Mode]Warren Hamilton
High content clinical trials involve dense sample collection and complex analyses from small patient numbers. They are important for early drug development and evaluation, addressing biological questions about target and pathway inhibition. Successful high content trials require standardized assays and infrastructure across sites, as well as collaboration between multiple institutions. Challenges include developing new science and technologies, building collaborative partnerships, and establishing operational and informatics systems for specimen and data management.
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
NCTR is a research center within the FDA that conducts toxicology research to support risk assessment and regulatory decision making. It has unique facilities including primate and BSL-3 laboratories. NCTR research focuses on emerging issues like nanotechnology, nutrition, and critical path initiatives. Bioimaging technologies like microPET and MRI are used to study effects of substances like ketamine anesthesia on brain development in primates. Studies found ketamine increased neuronal cell death markers in the frontal cortex of developing monkeys.
The document discusses challenges and opportunities in the development of biosimilars. It provides perspectives from several industry experts on the top hurdle being a lack of clarity around intellectual property and marketing strategies as well as high development costs. The experts note that developing the necessary skill sets around quality by design, analytics, and clinical trial design is key to overcoming hurdles in developing biosimilars safely and effectively.
The document provides information about the 12th Annual Conference and Exhibition on ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) addressing early ADME application strategies and discussing the latest screening and testing models. The event will take place on June 12-13, 2017 in London, UK and will feature speakers from major pharmaceutical companies discussing topics like predictive human toxicity, ADME/PK optimization, preclinical testing, developments in screening technology, and physiologically-based PK modeling. A half-day workshop on drug transporters will also be held on June 14.
This executive summary provides information on NanoScan Imaging, LLC (NSI), a company developing an iodinated nanoparticulate CT contrast agent called N1177. NSI is seeking $6.8 million in convertible debt financing to fund new formulations and intellectual property for N1177, which offers safety advantages over conventional CT contrast agents by lacking renal toxicity. NSI has assembled an experienced management team with backgrounds in drug development, licensing, and regulatory affairs to advance N1177 through clinical trials and commercialization.
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Similar to Innovation in Phase 1 Clinical Development (20)
One Week, One community: Shaping the future for Business Process Excellence & Performance!
Introducing one week and one combined approach to Business Process Excellence and Performance enhancement. Unlike 10 years ago, Lean, Six Sigma, BPM, along with all the historical quality and operational improvement approaches can no longer sit in silos. After the last few years of turmoil, businesses are once again looking to results – to performance, change and generating meaningful business opportunities and growth. Gone are the days where the tools were the be all and end all of Business Process Excellence. Now a new landscape is emerging placing Business Process Excellence as one of the key enablers to complete business transformation and revenue generation.
For more information about the Week, please visit http://ww.ProcessExcellenceLondon.co.uk, email enquire@iqpc.co.uk or call +44 (0)207 368 9300
Bringing together IQPC’s renowned 12th Annual Lean Six Sigma & Process Improvement Summit, the BPM Summit and the North American Process Excellence Awards, the newly conjoined Profit Through Process Week draws together everything your organizational team could need in 2011 to accelerate and progress Business Process Transformation.
Visit http://bit.ly/b4KKma for more information.
Pipeline Integrity Maintenance Forum 2010Elisa_Ramella
Oil & Gas IQ, a Worldwide Leader in Technical and Strategic Conferences and
Seminars, Launches the New “Pipeline Integrity Maintenance Forum 2010”
www.pipelineintegrityforum.com
Alternative approaches to developing strategic partnerships in order to drive discovery and innovation and enhance pipelines.
http://www.globaldiscoverycollaborations.com
This flyer advertises the Lean Six Sigma & Process Improvement Summit 2011 conference happening from January 17-20, 2011 in Orlando, Florida. The summit will focus on transforming business results through process optimization. Attendees can expect new content from the PI Visionary Council on the future of process excellence, maturity-led sessions, and executive leadership panels. Registering onsite provides an exclusive 2 for 1 registration offer plus a free workshop day and networking package. Individual and group registration options are listed along with payment and cancellation policies.
buy old yahoo accounts buy yahoo accountsSusan Laney
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
An introduction to the cryptocurrency investment platform Binance Savings.Any kyc Account
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Tastemy Pandit
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Recruiting in the Digital Age: A Social Media Masterclass
Innovation in Phase 1 Clinical Development
1. Register and pay before 11th June and save up to €450
is proud to present
Two Day Conference: 21st – 22nd September Conference Focus Day: 20th September
Marriott Hotel, Berliner Strasse 93, Munich, Germany
PraCtiCal aPPrOaChes tO eNgage With mOre thaN
WWW.Phase1CliNiCalDevelOPmeNt.COm
Phase i trial DevelOPmeNt tWeNty Pharma & BiOteCh
tO eNaBle Faster gO / NO-gO exPerts iNCluDiNg:
DeCisiONs, reDuCe COst aND Dr Paul Passier, Global Clinical Pharmacology Lead, Pain,
sPeeD time tO market Astellas
JW McBlane, Preclinical Assessor, Clinical Trials Unit, MHRA
key reasONs tO atteND: Dr Christen Steffen, Head of Preclinical Unit, BfArM
1) Get up to date on the latest regulations for submission criteria, Dr Walter Janssens, Senior Preclinical Assessor, Pre-
authorisation, Coordinator Early Phase Development, Federal
application processes and exploratory trials with case studies and a workshop
Agency for Medicines and Health Products
from the MHRA, BfArM and FAGGS
Birgitte Søgaard, Divisional Director – Clinical Pharmacology &
2) Discuss the most effective trial design methodologies to ensure rapid Translational Medicine, H. Lundbeck A/S
submission and approval timelines, with innovative methodologies from Michael- Friedrich Boettcher, Global Clinical Pharmacology
NicOx and Novartis Project Leader, Bayer Schering Pharma AG
Ludy van Beijsterveldt, Director Clinical Pharmacokinetics, and
3) Utilise preclinical data analysis: including PK/PD modelling, Pharmacology, Johnson and Johnson
metabolomics and translational methods to improve FIM predictions and
avoid errors. Share best practice with discussions and case studies from UCB, Jurgen Moll, R&D Oncology, Cell Biology, Nerviano Medical
Lundbeck, Servier and Johnson & Johnson Sciences
John Beaver, Senior Imaging Specialist, GlaxoSmithKline
4) Increase productivity and minimise costs through implementing Constance Hoefer, Independent Consultant
patient-based phase I trials: enhancing the selection and recruitment
processes and overcoming operational constraints Alessandra Vitaliti, Head of Cellular Biomarkers Group,
Novartis
5) Streamline the outsourcing process and establishing an effective working Paola Tocchetti, Director Drug Metabolism and
relationships with CROs; case study and discussion from Mubera Krijezi, Pharmacokinetics, NicOx Research Institute
Outsourcing Project Manager, Actelion Dr James Dow, Director of Clinical Pharmacology and DMPK,
(OSI) Prosidion
Dr Miroslav Ravic, Managing Director and CMO, Pharma
Integra and Affimed
Plus aN iNteraCtive Pre- Dr Ruth Oliver, Director and Head of Modelling and Simulation,
CONFereNCe DisCussiON Day: Global Exploratory Development, UCB
A) Regulatory workshop – gain access to 3 top European regulatory experts! Arun Mishra, Director Global Regulatory Affairs (Asia-Pacific,
Japan and Emerging Markets), GlaxoSmithKline
Jimmy Dr Walter Dr Christian
McBlane Janssens Steffen Reto Ossola, Group Leader for Biomarker Research, Biognosys
MHRA FAGGS BfArM
Dr Ansar Jawaid, Global Group Leader, R&D Genetics and
Personalised Medicine, AstraZeneca
Dr Richard Weaver, Scientific Director, Drug Safety
B) Don’t miss an exclusive biomarker focus day addressing all the key Assessment, Servier
questions surrounding early identification, development and validation of
biomarkers. Hear case studies from Novartis, GlaxoSmithKline, Jennifer Larsen, Translational Medicine Scientist, Lundbeck
Lundbeck and more Tony Gee, Director, PET & Radiotracer Development,
GlaxoSmithKline
Karin Meiser, Statistician, Novartis
meDia PartNers
Mubera Kreijzi, Senior Project Manager,
Clinical Pharmacology, Actelion
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.phase1clinicaldevelopment.com
2. Pre-CONFereNCe FOCus Day mONDay 20th sePtemBer 2010
BiOmarkers – eNhaNCiNg
iDeNtiFiCatiON aND DevelOPmeNt
PrOCesses tO eNsure a returN
ON iNvestmeNt
09.30 Registration and Coffee 12.10 Networking Lunch Break
10.00 Pharma IQ Welcome 13.30 Successfully Developing a Translatable Biomarker from
Preclinical to Phase I Studies
• How do in vitro studies relate to in vivo predictions and outcomes?
10.05 Opening Remarks from Chairperson; • Reaching the earliest possible go/no go decision
Alessandra Vitaliti, Head of Cellular Biomarkers Group, Novartis
Birgitte Søgaard,
10.10 Streamlining the Development and Validation Processes Divisional Director Clinical Pharmacology and
• Assessing the challenges faced when choosing to adopt a biomarker Translational Medicine, Lundbeck
• Usage of targeted mass spectrometry for early biomarker validation to
reduce financial and time burdens
• Outsourcing as a solution to biomarker development and validation
• Merging data across several studies to improve discovery rate 14.10 Case Study: Biomarkers for Kinase Inhibitors
Reto Ossola, Targeting the Cell Cycle
Group Leader for Biomarker Research, • Pre-defining your patient population using primary endpoints, PK and
Biognosys toxicology values
• Stratifying patients into improved responder groups
• Review of the field of different types of biomarkers used in the clinic
for cell cycle inhibitors
• Experiences and hurdles during transition from a preclinical towards a
10.50 Proof-of-Mechanism Biomarkers in Phase I Clinical Trials clinical biomarker
• Ex vivo stimulation concept for Proof-of-Mechanism in healthy subjects • A case study on biomarkers for Aurora kinase inhibitors
• Standardisation of customised flow cytometry-based biomarker
assays in multiple centre clinical studies
Jurgen Moll,
• Current examples of use of biomarkers in clinical practice R&D Oncology, Cell Biology,
Nerviano Medical Sciences
Alessandra Vitaliti,
Head of Cellular Biomarkers Group,
Novartis
14.50 Design of PET Biomarkers for In Vivo Imaging
• Overview of the PET technique
• How PET biomarkers are produced
11.30 Developing and Launching Personalised Healthcare Therapies • Biomarker design criteria: impact on the in vivo signal
- Lessons from AstraZeneca Tony Gee,
• Challenges across value chain
• Delivering personalized therapies globally Director, PET & Radiotracer Development,
• Case studies from AstraZeneca GlaxoSmithKline
Dr Ansar Jawaid,
Global Group Leader, R&D Genetics and Personalised Medicine,
AstraZeneca
15.10 Chairperson’s closing Remarks and End of Focus Day
Pre-CONFereNCe WOrkshOP 15.45 - 18.45
Regulatory Updates: Speeding Up the Application Process
This hands on workshop will allow attendees to interact directly with three top European regulators and discuss at length all of the latest regulations and their
impact on Phase I, as well as gaining insight into the differences between how applications are processed in the respective countries.
Jimmy Dr Walter Dr Christian
McBlane Janssens Steffen
MHRA FAGGS BfArM
You will walk away from this workshop with a more thorough understanding of:
• Protocol and quality considerations and what are the accepted submission criteria
• The preclinical requirements for entering into Phase I
• An assessor’s approach to assessing an application for the first clinical trial with a new agent
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.phase1clinicaldevelopment.com
3. CONFereNCe Day ONe tuesDay 21st sePtemBer 2010
08.15 Registration and Coffee
INNOVATIVE TRIAL DESIGNS: EFFECTIVE
09.00 Pharma IQ Welcome APPROACHES TO IMPROVE EFFICIENCY AND TIME
TO MARKET
09.05 Opening Remarks from Chairperson
Paola Tocchetti, Director Drug Metabolism and Pharmacokinetics, 12.10 Maximising Efficiency and Reducing Trial Time Through
NicOx Research Optimising Design; Combining Phases I and IIa
• Effective trial design and planning procedures
REGULATORY UPDATES: WHAT ARE THE CURRENT • Exploring new paradigms in trial design
ExPECTATIONS FOR PHASE I CLINICAL TRIALS? • Assessing the different considerations for trial designs using patients and volunteers
• Ensuring accurate and effective data via thorough design
• Employing more efficient design methodologies to speed time to market
09.10 Understanding Submission Criteria to Speed Up Approval Times
• Regulation updates: what impact is there on phase I? Paola Tocchetti,
• Enhancing communication between regulators and those involved in phase I trials Director Drug Metabolism and Pharmacokinetics,
• What data is expected for approval of different types of phase I trials? NicOx Research Institute
• Understanding patient safety considerations for a more successful trial
• Achieving effective compliance strategies to speed up approval times 12.40 Networking Lunch
Dr Christian Steffen,
Head of Preclinical Unit, BfArM 14.10 Combining Phase I and II Studies in a Single Trial Protocol
• The advantage and disadvantage of combining phase I and II studies
09.40 Regulatory Perspectives on Phase I: What has Changed and • Combining single ascending dose (SAD) and multiple ascending dose (MAD)
What are the Practical Implications? • Combining SAD, MAD and phase IIa
• Data sets for the transition from preclinical to clinical testing • Interaction with the regulatory authorities and ethics committees
• Recent changes in the regulatory environment and impact on processes • New trial designs with fixed and adaptive approaches (case study)
• An overview of exploratory clinical trial regulations Dr. Miroslav Ravic,
• Understanding the voluntary harmonisation procedure Managing Director,
• The clinical trial assessment process – what do assessors actually do? Pharma Integra
Jimmy McBlane,
Preclinical Assessor, 14.40 Sponsorship Spotlight
MHRA This is a unique opportunity to present on successful approaches and methodologies
that you have used to accelerate and enhance the innovation in phase I clinical development.
10.10 Regulatory Perspectives on Phase I Trials Conducted in For more information on how to sponsor this session please contact
Emerging Markets Nicola Ambler on:+44 (0)20 7368 9586 or nicola.ambler@iqpc.co.uk
• An overview of the regulatory frameworks in emerging markets
• Key challenges and opportunities when conducting phase I and exploratory 15.10 Use of Historical Placebo Data for the Design and Analysis of a
trials in emerging markets PoC Study in Osteoarthritis
• Enhancing trial efficiency through complete understanding of regulations • Meta-analysis of historical data on pain VAS score
and legislation • Use of the meta-analysis in the power calculation for the actual study
• Use of the meta-analysis in the analysis of the actual study
Arun Mishra, Director Global Regulatory Affairs
(Asia-Pacific, Japan and Emerging Markets), Karin Meiser,
GlaxoSmithKline Statistician,
Novartis
10.40 Networking Refreshment Break
15.40 Networking Refreshment Break
ASSESSING THE PRACTICAL AND BENEFICIAL
ASPECTS OF ExPLORATORY TRIALS IN ORDER TO OBTAINING PROOF OF CONCEPT THROUGH EFFICIENT
IMPLEMENT THEM SUCCESSFULLY AND MAKE FASTER IDENTIFICATION AND APPLICATION OF BIOMARKERS
GO/NO GO DECISIONS
16.10 Practical Approaches to Identify Clinically Relevant Biomarkers
11.10 Regulatory Experience with Exploratory Clinical Trials and Effectively Target the Right Patient Population
• Outlining critical issues in the trial application • An overview of animal disease models
• An overview of quality issues • Ensuring effective collaboration between research and development
• Evaluating the preclinical requirements • Applying companion diagnostics to assess patient response
• Protocol related submission criteria • Enhancing the implementation of statistical and design aspects
• Experience in Belgium with exploratory clinical trials: Birgitte Søgaard,
how are they dealt with by regulators? Divisional Director Clinical Pharmacology
Dr. Walter Janssens, Senior Preclinical Assessor, and Translational Medicine, Lundbeck
Pre-authorisation, Coordinator Early Phase Development,
Federal Agency for Medicines and Health Products 16.40 Employing Imaging in Phase I to Reduce Risk and Enable
Informed Decision Making
11.40 Bridging Non-Clinical Drug Safety to Humans: Microdosing • Optimising dosage for proof-of-concept studies
and Microtracer Studies • Use of imaging markers to differentiate candidate medications
• Making the decision: Phase 0 or Phase I? • Improving the efficacy of phase I trials through successful use of biomarkers
• Using microdosing to facilitate go/no go decisions John Beaver,
• Saving time and cost through the implementation of microtracer studies? Senior Imaging Specialist,
• Metabolites in Safety Testing (MIST) and microtracer studies GlaxoSmithKline
Richard J Weaver,
Scientific Director, Drug Safety Assessment, 17.10 Closing Remarks from Chairperson
Servier
17.25 Close of Day One
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.phase1clinicaldevelopment.com
4. CONFereNCe Day tWO WeDNesDay 22ND sePtemBer 2010
08.15 Registration and Coffee 13.00 Networking Lunch
09.00 Pharma IQ Welcome 14.00 BREAKOUT ROUNDTABLE DISCUSSIONS: Participants will be
09.05 Opening Remarks from Chairperson able to choose between the different roundtables and spend 45 minutes
Constance Hoefer, Independent Consultant discussing the points outlined below:
Roundtable A:
THE IMPORTANCE OF EFFECTIVE PRECLINICAL DATA Utilising more dynamic, flexible and collaborative trial designs to
ANALYSIS TO IMPROVE PREDICTIONS, ESTABLISH streamline trials and enhance time to market
PROOF OF CONCEPT AND ACHIEVE FASTER GO/NO Karin Meiser, Statistician, Novartis
GO DECISIONS Roundtable B:
Improving the efficiency of your selection process and effectively matching
09.10 Effective Approaches to PK/PD Modelling and Data Analysis your requirements and CRO capabilities
Avoiding Errors and Making Predictive Assessments Mubera Kreijzi, Senior Project Manager, Clinical Pharmacology, Actelion
• Current prediction methodologies from animal to man
• The value of comprehensive data analysis during early development WHEN AND HOW TO USE PATIENTS IN PHASE I
• Improving productivity through preclinical analysis TRIALS REDUCING COSTS AND IMPROVING GO/NO
• Effective error spotting at both preclinical and phase I stages GO DECISIONS
• Making accurate predictions using comprehensive PK/PD data and the associated
cost saving benefits
14.30 Enhancing Patient Recruitment Solutions for Use in
Ruth Oliver, Director and Head of Modeling and Simulation,
Global Exploratory Development, UCB
Phase I Trials
• An overview of current use of patients in phase I
09.40 Metabolomic Studies to Confirm Clinical Candidate Selection • Identifying eligible patient subjects
• Assessing the suitability of using patients in phase I per therapeutic area
• Short overview of candidate optimisation and quality; what are the on/off target
• Optimising patient recruitment strategies
effects, PD/Tox and DMPK profile?
• Overcoming geographical constraints during patient recruitment
• Analysis of late stage failures, including imbalance of on/off target effects
• Comparing dosage and PK/PD data in healthy volunteers and in patients:
and contributing factors
what is the relevance?
• Using metabolomic studies to powerfully resolve species-specific pathways
and products of metabolism (case studies) Michael-Friederich Boettcher, Global Clinical Pharmacology Leader,
• Metabolomics in humanised animal models reveal on/off target effects (case studies) Bayer Schering Pharma
• Analysing clinical trial populations through metabolomics - biomarkers of individual
variability, disease, efficacy and toxicity 15.00 Challenges and Benefits of Patient-Based Phase I Trials
Constance Hoefer, • Understanding the regulations surrounding patient-based phase I trials
Independent Consultant • Operational constraints involved in conducting phase I in patients
• Combining DDI studies in phase I to allow concomitant medication in patients
10.10 Improving Dosage Predictions for First in Man Studies • Expanding phase I trials in patients to a wider range of therapeutic indications
Using A Physiologically Based Approach • Expediting trial development and reducing costs through use of patients in phase I
• Evaluating in vitro in vivo correlations James Dow, Director of Clinical Pharmacology & DMPK,
• Optimising the use of preclinical data to get mechanistic understanding of PK behaviour (OSI) Prosidion
• Applying physiologically based PK (PBPK) modelling for prediction of human PK
• Selecting FIM dosage using MABEL (minimum anticipated biological effect 15.30 Networking Refreshment Break
level) approach
Vikash Sinha, Clinical Pharmacology Leader, 16.00 Methods of Patient Selection to Improve the Responder
Johnson&Johnson Rate in Early-Sign-of Efficacy Studies in Pain
• An overview of the core challenges faced during patient selection
10.50 Networking Refreshment Break • How to increase the reliability of the response to enhance trial efficiency
• Effective solutions to select potential responders
11.30 Successful Translation from Preclinical Studies to
Phase I Trials Dr. Paul Passier, Global Clinical Pharmacology Lead,
• Taking a multidisciplinary approach to reaching a proof of concept Pain, Astellas
• Methodologies used to predict results from animal to human
• Overcoming the complexities of translating from animal to human subjects PHASE I TRIALS IN ONCOLOGY: CASE STUDY ExAMPLES
• Using modelling, simulation and PKPD investigations to facilitating go/no go
decisions at an early stage 16.30 Resistance Mechanisms of Targeted Therapies
• Assessing animal data, toxicity and toxicokinetic data to ensure appropriate • Similarities and differences in resistance mechanisms comparing targeted
dose ranges in FIM studies compared to classical cytotoxic therapies
• Making accurate predictions using comprehensive PK/PD data and the • Preclinical and clinical case studies of kinase inhibitors
associated cost saving benefits • Approaches to address resistances early in drug development
Jennifer Larsen, Translational Medicine Scientist, Jurgen Moll, R&D Oncology, Cell Biology,
Lundbeck Nerviano Medical Sciences
12:00 Sponsorship Spotlight 17.00 Effective Approaches to PK/PD in Early Oncology Development
This is a unique opportunity to present on successful approaches and methodologies
• PKPD model based FIH oncology drug development strategies
that you have used to accelerate and enhance the innovation in phase I clinical development.
• Evaluating PKPD and biomarkers
For more information on how to sponsor this session please contact • Utilising preclinical PKPD in support of observations in patients
Nicola Ambler on:+44 (0)20 7368 9586 or nicola.ambler@iqpc.co.uk • Improving animal to man predictions
• Implementing PKPD modelling and simulation to facilitate decision
IMPROVING PHASE I TRIAL OPERATIONS – making during early development
OUTSOURCING AND RELATIONSHIP MANAGEMENT Ludy van Beijsterveldt, Director Clinical Pharmacology, Oncology,
12.30 Enhancing CRO Selection & Management to Improve Trial Success Johnson & Johnson
• Identifying a CRO to match the requirements of your trial
• Optimising selection processes 17.30 Closing Remarks from Chairperson
• Ensuring an effective working relationship with your CRO
• Facilitating approval process and decreasing workload through effective CRO selection 17.45 Close of Day Two
Mubera Krijezi, Senior Project Manager, Clinical Pharmacology,
Actelion
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.phase1clinicaldevelopment.com
5. sPONsOrs aND exhiBitOrs
Who should attend Directors, senior managers and managers from the following
areas within pharmaceutical manufacturers and biotech
companies with responsibility for:
• Clinical Pharmocology • Exploratory Medicine
• Clinical Research • Translational Medicine
• PK/PD • Biomarker Development
• Clinical Operations
about Pharma iQ
Become a member of Pharma IQ and receive complimentary access
to resources that will keep you at the forefront of industry change.
You will receive access to our growing library of multi-media
presentations from industry leaders, an email newsletter updating
you on new content that has been added, free aggregated news feed
from over 1000 global news sources tracking your industry and
special member only discounts on events.
Become a member here:
Web: www.pharma-iq.com Phone: +44(0)20 7368 9300
sponsorship Opportunities Why Now?
Innovation in Phase I Clinical Development will be attended With the focus on cost control more important than ever, phase
by senior officials and decision-makers from industry I clinical trials are becoming an increasingly crucial cog in the
worldwide, bringing together buyers and suppliers in one drug development process as the bid to save time and money
location. Focused and high-level, the event will be an excellent has spurred innovation in trial design and processes at all levels.
platform to initiate new business relationships. With tailored Indeed, investment in phase I has the potential to reduce overall
networking, sponsors can achieve the face-to-face contact costs by enabling faster go/no go decisions, which is why 40%
that overcrowded trade shows cannot deliver. Exhibiting and of trials are now in phase I and the pressure is on to deliver
sponsorship options are extensive, and packages can be results at an early stage. The Innovation in Phase I Clinical
tailor-made to suit your individual company’s needs. Development conference offers the opportunity to discover new
methodologies, cost saving strategies and clarify changes to
For more information please contact sponsorship
the regulatory landscape in a bid to reach proof of concept and
on +44 (0)207 368 9300 or email sponsorship@iqpc.com
make go/no go decisions as soon as possible.
What Does Pharma iQ’s
innovation in Phase i Clinical
Development Offer?
This conference provides a unique platform for drug developers to
discuss practical, proven ideas to save time and money and ensure
that companies have the knowledge they need to take their drugs to
market fast.
This case study driven agenda will help you uncover ways to make
the incremental improvements to your clinical trials that can greatly
reduce the time it takes to get your treatments to market.
WWW.Phase1CliNiCalDevelOPmeNt.COm
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.phase1clinicaldevelopment.com
6. 5 Ways to Register
Freephone: 0800 652 2363 or
+44 (0)20 7368 9300
Two Day Conference: 21st – 22nd September Conference Focus Day: 20th September Fax: +44 (0)20 7368 9301
Marriott Hotel, Berliner Strasse 93, Munich, Germany
Post: your booking form to
IQPC Ltd. Anchor House,
To speed registration, please provide the priority code located on the mailing label or in the box below.
15-19 Britten Street,
My registration code is PDFW London SW3 3QL
Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration
code above to inform us of any changes or to remove your details. Email: enquire@iqpc.co.uk
Web:
www.phase1clinicaldevelopment.com
Book and Pay by Book and Pay Standard
Packages
June 11th 2010* by July 9th 2010* Price
Conference + Focus Day and Workshop with SAVe €450 SAVe €350 €4197 + VAT
Team Discounts*
Full access to Conference Recordings ** €3747 + VAT €3847 + VAT IQPC recognises the value of learning in teams. Groups of 3 or more
Conference + Focus Day SAVe €400 SAVe €300 €3647 + VAT booking at the same time from the same company receive a 10%
and Workshops €3247 + VAT €3347 + VAT £1397 +VAT discount. 5 or more receive a 15% discount. 7 receive a 20% discount.
Conference + Workshop + Full access Save £50
SAVe €300 SAVe €200 €3098 + VAT Only one discount available per person.
to conference recordings ** €2798 + VAT
£649 +VAT €2898 + VAT £1048 +VAT
Conference + Focus Day + Full access SAVe €350
Save £150 SAVe €250
€3548 + VAT
Venue & Accommodation
to conference recordings ** €3198 + VAT €3298 + VAT £699 +VAT
£2447 +VAT VENUE: München Marriott Hotel, Berliner Strasse 93, München, 80805,
Conference + Workshop
SAVe €250 SAVe €150 €2548 + VAT Deutschland. Tel: +49 89 360020 Fax: +49 89 36002200
€2298 + VAT €2398 + VAT ACCOMMODATION: Hotel accommodation is not included in the conference
SAVe €300 SAVe €200 fee. To book accommodation at Marriott Munich, Telephone +49 89 360020 or
Conference + Focus Day €2998 + VAT
€2698 + VAT €2798 + VAT online: www.marriott-munich.com. All rooms are subject to availability during
Conference + Full Access to SAVe €200 SAVe €100 Oktoberfest. Or for a further selection of hotels in Munich search:
Conference Recordings* €2249 + VAT €2349 + VAT £2098 +VAT + VAT
€2449 www.4cityhotels.com/munich.html
TAKE ADVANTAGE OF MUNICH’S WORLD RENOWNED
SAVe €150 €1899 + VAT OKTOBERFEST FESTIVAL TAKING PLACE OVER THE SAME DATES
Conference Only
€1749 + VAT €1899 + VAT
* To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction
Free Online Resources
with any other offer. German VAT is charged at 19%. VAT Registration # DE 261 1019 14 To claim a variety of articles, podcasts and other free resources please
visit www.phase1clinicaldevelopment.com
Delegate Details Digital Conference On CD-ROM
Please photocopy for each additional delegate A digital version of the conference proceedings, including all
6 Mr 6 Mrs 6 Miss 6 Ms 6 Dr 6 Other
presentations, is available to buy.
6 I cannot attend the event, please send me the CD Rom priced at
First Name Family Name £599 plus VAT
Job Title Recent digital conferences available - £599 plus VAT each
Tel No. 6 Global Clinical Outsourcing Forum
Email 6 Clinical Data Standardisation and Management
6 Yes I would like to receive information about products and services via email 6 Optimising Clinical Development in Oncology
Organisation
6 Paediatric Clinical Development
6 Please send me conference materials indicated above
Nature of business
6 I have filled out credit card details below
Address For further information
Postcode Country Please call: 0207 368 9300
Telephone Fax or email: knowledgebank@iqpc.co.uk.
Approving Manager To search IQPC’s archived conference documentation
Name of person completing form if different from delegate: visit: www.iqpcknowledgebank.com
Signature Terms and Conditions
I agree to IQPC’s cancellation, substitution and payment terms Please read the information listed below as each booking is subject to IQPC Ltd standard terms and
Special dietary requirements: 6 Vegetarian 6 Non-dairy 6 Other (please specify) conditions. Payment Terms: Upon completion and return of the registration form, full payment is
required no later than 5 business days from the date of invoice. Payment of invoices by means other
Please indicate if you have already registered by Phone 6 Fax 6 Email 6 Web 6 than by credit card, or purchase order (UK Plc and UK government bodies only) will be subject to
Please note: if you have not received an acknowledgement before the conference, please call us to confirm your booking. a €65 (plus VAT) per delegate processing fee. Payment must be received prior to the conference
date. We reserve the right to refuse admission to the conference if payment has not been received.
IQPC Cancellation, Postponement and Substitution Policy: You may substitute delegates
at any time by providing reasonable advance notice to IQPC. For any cancellations received in
Payment Method writing not less than eight (8) days prior to the conference, you will receive a 90% credit to be
used at another IQPC conference which must occur within one year from the date of issuance
Total price for your Organisation: (Add total of all individuals attending): of such credit. An administration fee of 10% of the contract fee will be retained by IQPC for all
permitted cancellations. No credit will be issued for any cancellations occurring within seven (7)
Card Number: VISA 6 M/C 6 AMEX 6 days (inclusive) of the conference. In the event that IQPC cancels an event for any reason, you will
receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event
6666666666666666 to be mutually agreed with IQPC, which must occur within one year from the date of cancellation.
In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling
Exp. Date: 6 6 6 6 Sec: 6 6 6 6
to attend in on the rescheduled date, you will receive a credit for 100% of the contract fee paid.
Conference code 18890.001
You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur
within one year from the date of postponement. Except as specified above, no credits will be issued
Name On Card: Signature: for cancellations. There are no refunds given under any circumstances. IQPC is not responsible
for any loss or damage as a result of a substitution, alteration or cancellation/postponement of
an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled,
Billing Address (if different from below): rescheduled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any
other event that renders performance of this conference impracticable, illegal or impossible. For
purposes of this clause, a fortuitous event shall include, but not be limited to: war, fire, labour
City/County/Postcode Cheque enclosed for: € (Made payable to IQPC Ltd.) strike, extreme weather or other emergency. Please note that while speakers and topics were
confirmed at the time of publishing, circumstances beyond the control of the organizers may
necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, IQPC
(Please quote 18890.001 with remittance advice) reserves the right to alter or modify the advertised speakers and/or topics if necessary without any
IQPC Bank details: HSBC Bank, 67 George Street, Richmond, Surrey, TW9 1HG. United Kingdom. liability to you whatsoever. Any substitutions or alterations will be updated on our web page as soon
as possible. Discounts: All ‘Early Bird’ Discounts require payment at time of registration and before
Sort Code: 40 05 15, Account No: 59090618, IBAN Code: GB98 MIDL 4005 1559 0906 18 the cut-off date in order to receive any discount. Any discounts offered whether by IQPC (including
Swift Code: MIDLGB22 Account name: International Quality & Productivity Centre Ltd. team discounts) must also require payment at the time of registration. All discount offers cannot be
combined with any other offer.
PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE